333 related articles for article (PubMed ID: 19698900)
1. Desvenlafaxine: a new serotonin-norepinephrine reuptake inhibitor for the treatment of adults with major depressive disorder.
Perry R; Cassagnol M
Clin Ther; 2009 Jun; 31 Pt 1():1374-404. PubMed ID: 19698900
[TBL] [Abstract][Full Text] [Related]
2. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
[TBL] [Abstract][Full Text] [Related]
3. Desvenlafaxine succinate: a newer antidepressant for the treatment of depression and somatic symptoms.
Seo HJ; Sohi MS; Patkar AA; Masand PS; Pae CU
Postgrad Med; 2010 Jan; 122(1):125-38. PubMed ID: 20107296
[TBL] [Abstract][Full Text] [Related]
4. Desvenlafaxine succinate for major depressive disorder: a critical review of the evidence.
Kamath J; Handratta V
Expert Rev Neurother; 2008 Dec; 8(12):1787-97. PubMed ID: 19086875
[TBL] [Abstract][Full Text] [Related]
5. Clinical utility of desvenlafaxine 50 mg/d for treating MDD: a review of two randomized placebo-controlled trials for the practicing physician.
Reddy S; Kane C; Pitrosky B; Musgnung J; Ninan PT; Guico-Pabia CJ
Curr Med Res Opin; 2010 Jan; 26(1):139-50. PubMed ID: 19919295
[TBL] [Abstract][Full Text] [Related]
6. Short-term efficacy and safety of desvenlafaxine in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder.
Kornstein SG; Jiang Q; Reddy S; Musgnung JJ; Guico-Pabia CJ
J Clin Psychiatry; 2010 Aug; 71(8):1088-96. PubMed ID: 20797382
[TBL] [Abstract][Full Text] [Related]
7. Desvenlafaxine in the treatment of major depressive disorder.
Pae CU
Expert Opin Pharmacother; 2011 Dec; 12(18):2923-8. PubMed ID: 22098230
[TBL] [Abstract][Full Text] [Related]
8. Discontinuation symptoms and taper/poststudy-emergent adverse events with desvenlafaxine treatment for major depressive disorder.
Montgomery SA; Fava M; Padmanabhan SK; Guico-Pabia CJ; Tourian KA
Int Clin Psychopharmacol; 2009 Nov; 24(6):296-305. PubMed ID: 19779354
[TBL] [Abstract][Full Text] [Related]
9. Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial.
Boyer P; Montgomery S; Lepola U; Germain JM; Brisard C; Ganguly R; Padmanabhan SK; Tourian KA
Int Clin Psychopharmacol; 2008 Sep; 23(5):243-53. PubMed ID: 18703933
[TBL] [Abstract][Full Text] [Related]
10. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder.
Septien-Velez L; Pitrosky B; Padmanabhan SK; Germain JM; Tourian KA
Int Clin Psychopharmacol; 2007 Nov; 22(6):338-47. PubMed ID: 17917552
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomized controlled trial.
Speroff L; Gass M; Constantine G; Olivier S;
Obstet Gynecol; 2008 Jan; 111(1):77-87. PubMed ID: 18165395
[TBL] [Abstract][Full Text] [Related]
12. Desvenlafaxine: another "me too" drug?
Sopko MA; Ehret MJ; Grgas M
Ann Pharmacother; 2008 Oct; 42(10):1439-46. PubMed ID: 18698015
[TBL] [Abstract][Full Text] [Related]
13. Desvenlafaxine for the prevention of relapse in major depressive disorder: results of a randomized trial.
Rickels K; Montgomery SA; Tourian KA; Guelfi JD; Pitrosky B; Padmanabhan SK; Germain JM; Leurent C; Brisard C
J Clin Psychopharmacol; 2010 Feb; 30(1):18-24. PubMed ID: 20075643
[TBL] [Abstract][Full Text] [Related]
14. Desvenlafaxine for depression.
Med Lett Drugs Ther; 2008 May; 50(1286):37-9. PubMed ID: 18487957
[No Abstract] [Full Text] [Related]
15. Assessing the efficacy of desvenlafaxine for improving functioning and well-being outcome measures in patients with major depressive disorder: a pooled analysis of 9 double-blind, placebo-controlled, 8-week clinical trials.
Soares CN; Kornstein SG; Thase ME; Jiang Q; Guico-Pabia CJ
J Clin Psychiatry; 2009 Oct; 70(10):1365-71. PubMed ID: 19906341
[TBL] [Abstract][Full Text] [Related]
16. A pooled analysis of the efficacy of desvenlafaxine for the treatment of major depressive disorder in perimenopausal and postmenopausal women.
Kornstein SG; Clayton AH; Bao W; Guico-Pabia CJ
J Womens Health (Larchmt); 2015 Apr; 24(4):281-90. PubMed ID: 25860107
[TBL] [Abstract][Full Text] [Related]
17. Efficacy, safety, and tolerability of a triple reuptake inhibitor GSK372475 in the treatment of patients with major depressive disorder: two randomized, placebo- and active-controlled clinical trials.
Learned S; Graff O; Roychowdhury S; Moate R; Krishnan KR; Archer G; Modell JG; Alexander R; Zamuner S; Lavergne A; Evoniuk G; Ratti E
J Psychopharmacol; 2012 May; 26(5):653-62. PubMed ID: 22048884
[TBL] [Abstract][Full Text] [Related]
18. [Non-hormonal treatment for vasomotor symptoms during menopause: role of desvenlafaxine].
Lilue M; Palacios S
Ginecol Obstet Mex; 2009 Oct; 77(10):475-81. PubMed ID: 19902676
[TBL] [Abstract][Full Text] [Related]
19. A 10-month, open-label evaluation of desvenlafaxine in Japanese outpatients with major depressive disorder.
Tourian K; Wang Y; Ii Y
Int Clin Psychopharmacol; 2013 Jul; 28(4):206-13. PubMed ID: 23587982
[TBL] [Abstract][Full Text] [Related]
20. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder.
Perahia DG; Pritchett YL; Kajdasz DK; Bauer M; Jain R; Russell JM; Walker DJ; Spencer KA; Froud DM; Raskin J; Thase ME
J Psychiatr Res; 2008 Jan; 42(1):22-34. PubMed ID: 17445831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]